Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).

This is because the eligible population size is small, around 30 people, all of whom may receive treatment each year.

The company has a commercial arrangement (simple discount patient access scheme). This makes dinutuximab beta available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme contact customerservice-uk@eusapharma.com.

Dinutuximab is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 22 August 2018